Axitinib (AG 013736)

Name: Axitinib (AG 013736)
Brand: Selleck Chemicals
SKU: S1005
Rating: 5 (112 reviews)

For research use only.

Licensed by Pfizer Catalog No.S1005

112 publications

CAS No. 319460-85-0

Axitinib (AG 013736) is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.

Selleck's Axitinib (AG 013736) has been cited by 112 publications

Cell, 2018, 173(1):74-89

PubMed: 29570999 ( click the link to review the publication )

Cell, 2018, 173(1):117-129

PubMed: 29570992 ( click the link to review the publication )

Cancer Discov, 2012, 2(4):344-55

PubMed: 22576211 ( click the link to review the publication )

J Clin Invest, 2021, 131(8)139434

PubMed: 33855973 ( click the link to review the publication )

Theranostics, 2021, 11(10):4975-4991

PubMed: 33754039 ( click the link to review the publication )

Elife, 2021, 10e67315

PubMed: 34085926 ( click the link to review the publication )

Cancers (Basel), 2021, 13(9)2009

PubMed: 33921957 ( click the link to review the publication )

J Clin Endocrinol Metab, 2021, dgab020

PubMed: 33524147 ( click the link to review the publication )

Hum Mol Genet, 2021, ddab011

PubMed: 33438013 ( click the link to review the publication )

Front Oncol, 2021, 11:650052

PubMed: 34094940 ( click the link to review the publication )

Cancer Immunol Immunother, 2021, 10.1007/s00262-021-02992-7

PubMed: 34160685 ( click the link to review the publication )

Cancer Gene Ther, 2021, 10.1038/s41417-021-00345-1

PubMed: 34088993 ( click the link to review the publication )

Drug Metab Dispos, 2021, 49(1):53-61

PubMed: 33148688 ( click the link to review the publication )

Biomedicines, 2021, 9(6)627

PubMed: 34072926 ( click the link to review the publication )

Oncotarget, 2021, 12(7):674-685

PubMed: 33868588 ( click the link to review the publication )

Nat Commun, 2021, 12(1):808

PubMed: 33547292 ( click the link to review the publication )

Dev Biol, 2021, 473:80-89

PubMed: 33577829 ( click the link to review the publication )

Mol Cell, 2020, 80(6):1104-1122.e9

PubMed: 33259812 ( click the link to review the publication )

Clin Cancer Res, 2020, 20 pii: clincanres

PubMed: 32312893 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Biomaterials, 2020, 237:119793

PubMed: 32044521 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3172

PubMed: 33126775 ( click the link to review the publication )

Br J Cancer, 2020, 22

PubMed: 32439932 ( click the link to review the publication )

Front Cell Dev Biol, 2020, 8:578

PubMed: 32733887 ( click the link to review the publication )
Aging (Albany NY), 2020, 7;12(9):8221-8240

PubMed: 32379705 ( click the link to review the publication )

Aging (Albany NY), 2020, 13(1):1096-1119

PubMed: 33291075 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Toxicol In Vitro, 2020, 71:105063

PubMed: 33271325 ( click the link to review the publication )

Molecules, 2020, 26(1)E35

PubMed: 33374788 ( click the link to review the publication )

Burns Trauma, 2020, 8:tkaa025

PubMed: 33150188 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Cell Rep, 2020, 32(2):107906

PubMed: 32668247 ( click the link to review the publication )

Exp Ther Med, 2020, 19(2):1336-1342

PubMed: 32010307 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(4):2402-2415

PubMed: 31957261 ( click the link to review the publication )

Neoplasia, 2020, 22(10):470-483

PubMed: 32818841 ( click the link to review the publication )

Dev Cell, 2019, 48(2):151-166.e7

PubMed: 30639056 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2019, 116(25):12353-12362

PubMed: 31152134 ( click the link to review the publication )

ACS Appl Mater Interfaces, 2019, 101021/acsami9b20178

PubMed: 31816241 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )

Int J Cancer, 2019, 145(7):1991-2001

PubMed: 30848481 ( click the link to review the publication )

Lab Chip, 2019, 19(12):2071-2080

PubMed: 31049508 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):322

PubMed: 31331377 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-18-1319

PubMed: 31594826 ( click the link to review the publication )

Hum Mol Genet, 2019, 10.1093/hmg/ddz152

PubMed: 31518391 ( click the link to review the publication )

Pharmacol Res, 2019, 144:292-305

PubMed: 31048033 ( click the link to review the publication )

J Immunol, 2019, 203(10):2630-2643

PubMed: 31586036 ( click the link to review the publication )

J Cell Physiol, 2019, 10.1002/jcp.28810

PubMed: 31093976 ( click the link to review the publication )
Int J Nanomedicine, 2019, 14:441-455

PubMed: 30666106 ( click the link to review the publication )

J Cell Mol Med, 2019, 23(2):920-933

PubMed: 30394679 ( click the link to review the publication )

Plast Reconstr Surg, 2019, 143(1):126-135

PubMed: 30303928 ( click the link to review the publication )

Naunyn Schmiedebergs Arch Pharmacol, 2019, 10.1007/s00210-019-01746-8

PubMed: 31655854 ( click the link to review the publication )

Commun Biol, 2019, 2:170

PubMed: 31098403 ( click the link to review the publication )

Cancer Immunol Res, 2019, 7(9):1523-1534

PubMed: 31266784 ( click the link to review the publication )

Assay Drug Dev Technol, 2019, 17(4):167-177

PubMed: 31184962 ( click the link to review the publication )

Nat Commun, 2018, 9(1):5009

PubMed: 30479336 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):974

PubMed: 30250188 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(7):1405-1415

PubMed: 29695637 ( click the link to review the publication )

J Cell Physiol, 2018, 233(3):2067-2074

PubMed: 28294324 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2018, 314(5):C589-C602

PubMed: 29351406 ( click the link to review the publication )

Cell Biol Int, 2018, 42(11):1511-1522

PubMed: 30080297 ( click the link to review the publication )

Biomed Chromatogr, 2018, 32(6):e4184

PubMed: 29283445 ( click the link to review the publication )

Oncol Lett, 2018, 15(5):6107-6114

PubMed: 29731842 ( click the link to review the publication )

Oncotarget, 2018, 9(89):35962-35973

PubMed: 30542510 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(11):2934-2939

PubMed: 28246332 ( click the link to review the publication )

Cancer Res, 2017, 77(5):1212-1226

PubMed: 28087600 ( click the link to review the publication )

Theranostics, 2017, 7(16):3972-3988

PubMed: 29109792 ( click the link to review the publication )

Oncogene, 2017, 10.1038/onc.2017.132

PubMed: 28481872 ( click the link to review the publication )

Br J Cancer, 2017, 117(5):e3

PubMed: 28704838 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

Cell Chem Biol, 2017, 24(7):858-869

PubMed: 28669525 ( click the link to review the publication )

Hum Mol Genet, 2017, 26(22):4375-4387

PubMed: 28973155 ( click the link to review the publication )
Front Oncol, 2017, 7:182

PubMed: 28879167 ( click the link to review the publication )

Cell Biosci, 2017, 7:43

PubMed: 28852468 ( click the link to review the publication )

Eur Radiol, 2017, 27(3):918-926

PubMed: 27287476 ( click the link to review the publication )

Chem Biodivers, 2017, 14(3)

PubMed: 27936296 ( click the link to review the publication )

Oncotarget, 2017, 9(5):5529-5544

PubMed: 29464016 ( click the link to review the publication )

Neural Regen Res, 2017, 12(11):1816-1822

PubMed: 29239327 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(8):1940-50

PubMed: 26578684 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(33):9339-44

PubMed: 27482107 ( click the link to review the publication )

Cancer Res, 2016, 76(11):3200-10

PubMed: 27197162 ( click the link to review the publication )

Cancer Res, 2016, 76(1):117-26

PubMed: 26677977 ( click the link to review the publication )

PLoS Genet, 2016, 12(9):e1006279

PubMed: 27588951 ( click the link to review the publication )

J Immunol, 2016, 197(2):504-16

PubMed: 27279371 ( click the link to review the publication )

Sci Rep, 2016, 6:24453

PubMed: 27076230 ( click the link to review the publication )

CNS Neurosci Ther, 2016, 22(6):440-50

PubMed: 26861512 ( click the link to review the publication )

Cellular Signalling, 2016, 19;28(6):652-662

PubMed: 27006333 ( click the link to review the publication )

Oncotarget, 2016, 7(18-:25983-6002

PubMed: 27036020 ( click the link to review the publication )

Mol Nutr Food Res, 2015, 59(11):2255-66

PubMed: 26255647 ( click the link to review the publication )

Sci Rep, 2015, 5:16622

PubMed: 26564777 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2015, 56(5):3140-8

PubMed: 26024097 ( click the link to review the publication )

PLoS One, 2015, 10(10):e0140310

PubMed: 26461489 ( click the link to review the publication )

PLoS One, 2015, 10(6):e0128897

PubMed: 26042424 ( click the link to review the publication )

Anal Chem, 2014, 86(17):8842-9

PubMed: 25118958 ( click the link to review the publication )

J Cell Biochem, 2014, 10.1002/jcb.25066

PubMed: 25536282 ( click the link to review the publication )
Drug Des Devel Ther, 2014, 8:1107-23

PubMed: 25170251 ( click the link to review the publication )

PLoS One, 2014, 9(1):e85759

PubMed: 24454929 ( click the link to review the publication )

Gene Expression Patterns , 2014, 16(2):93-103

PubMed: 25460514 ( click the link to review the publication )

Oncotarget, 2014, 5(16):6801-15

PubMed: 25149535 ( click the link to review the publication )

J Nucl Med, 2013, 54(9):1630-6

PubMed: 23907757 ( click the link to review the publication )

Sci Signal, 2013, 6(271):ra25

PubMed: 23592840 ( click the link to review the publication )

Br J Cancer, 2013, 110(4):894-8

PubMed: 24398510 ( click the link to review the publication )

Development, 2013, 140(20):4214-25

PubMed: 24026121 ( click the link to review the publication )

Acta Oncol, 2013, 53(5):637-45

PubMed: 24041258 ( click the link to review the publication )

Histochem Cell Biol, 2013, 139(3):431-45

PubMed: 23052841 ( click the link to review the publication )

J Labelled Comp Radiopharm, 2013, 56(2):42-9

PubMed: 24285281 ( click the link to review the publication )

Glia, 2012, 60(6):936-47

PubMed: 22431192 ( click the link to review the publication )

Cancer Sci, 2012, 103(3):433-8

PubMed: 22098620 ( click the link to review the publication )

Mol Med, 2012, 18:887-98

PubMed: 22549112 ( click the link to review the publication )

Cells Tissues Organs, 2012, 196(3):195-205

PubMed: 22433970 ( click the link to review the publication )

J Biomol Screen, 2011, 16(2):141-54

PubMed: 21297102 ( click the link to review the publication )

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description

Features

Superior as second-line therapy relative to sorafenib (current standard-of-care).

Targets

VEGFR1/FLT1 ^[1] (Porcine aorta endothelial cells)	VEGFR2/Flk1 ^[1] (Porcine aorta endothelial cells)	VEGFR2/KDR ^[1] (Porcine aorta endothelial cells)	VEGFR3 ^[1] (Porcine aorta endothelial cells)	PDGFRβ ^[1] (Porcine aorta endothelial cells)	View More
0.1 nM	0.18 nM	0.2 nM	0.1 nM-0.3 nM	1.6 nM	View More

In vitro

Axitinib could block the cellular autophosphorylation of VEGFR and VEGF-mediated endothelial cell viability, tube formation, and downstream signaling. Axitinib inhibits the proliferation of variable cell lines with IC50 of >10,000 nM (IGR-N91), 849 nM (IGR-NB8), 274 nM (SH-SY5Y) and 573 nM (non-VEGF stimulated HUVEC). ^[2]

Cell Data

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
EoL-1-cell	NHrKdHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFXySlZKSzVyPUCuNFAxODVzMzFOwG0>	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
NCI-H1703	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3\DVWlEPTB;MD6wNFA6ODJizszN	NYfzdZFQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
KASUMI-1	NIDVZ5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnvQTWM2OD1yLkCwOlgzKM7:TR?=	MmLsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
CGTH-W-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1jiOmlEPTB;MD6wNFczOiEQvF2=	M1i5ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
A204	NIC1S4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3nZdmlEPTB;MD6wNFk6OiEQvF2=	M1W1WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
HOP-62	NH3XO2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MYXJR\|UxRTBwMUC4N\|Yh\|ryP	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
H-EMC-SS	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MmrRTWM2OD1yLkGxNFA2KM7:TR?=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
KU812	NWTOSGxpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmXtTWM2OD1yLkG2OVc4KM7:TR?=	M3vJUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
EM-2	NVrVTWhNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MljOTWM2OD1yLkG2PFE3KM7:TR?=	NWjq[ZhsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
LAMA-84	NV74bIRwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3XmZWlEPTB;MD6xO\|Y3PSEQvF2=	NFL0UJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
JAR	Mn7MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXXJR\|UxRTBwMkO5PFkh\|ryP	M1ywfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
G-361	M{iwTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGOx[INKSzVyPUCuN\|I{OjVizszN	MlzBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
KG-1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mnu2TWM2OD1yLkO3OlQzKM7:TR?=	NELXbVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
BV-173	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUCxS\|JpUUN3ME2wMlM6OzJizszN	M3fZU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
K5	M1nSXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVjZTWhDUUN3ME2wMlQzOTJ5IN88US=>	M3r5[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
MEG-01	NE\FcJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHLhRXNKSzVyPUCuOFI{PjFizszN	NHz1So09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
MFM-223	M2C0Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M37jTWlEPTB;MD60OFc4PiEQvF2=	M{f5WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
BE-13	MlG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MULJR\|UxRTBwNUGwNFgh\|ryP	NIjpVlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
NEC8	MoLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXnXWoQ1UUN3ME2wMlczOTF\|IN88US=>	MkW5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
SW756	NEnwPZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlHvTWM2OD1yLkm5PFQ3KM7:TR?=	NX;jUJJIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
A2780	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVqzdIhiUUN3ME2xMlAyOTR4IN88US=>	NWXLVVZkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
NB14	MnnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnfyTWM2OD1zLkCxPFAyKM7:TR?=	NWexeVdrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
H4	M1XCc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUjJR\|UxRTFwME[0NlIh\|ryP	M4fSUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
SK-OV-3	MmTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2LxT2lEPTB;MT6wOlY{OyEQvF2=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
AN3-CA	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHvyTINKSzVyPUGuNFg{QDlizszN	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
A427	M{Xzc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3XUb2lEPTB;MT6xNFM5OSEQvF2=	NWjoOYhERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
ES7	M{fob2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVzqTHk3UUN3ME2xMlEyOzN2IN88US=>	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
AGS	M4Lpd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MWrJR\|UxRTFwMUGzPVUh\|ryP	MlS4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
G-402	NWHDWHR1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NEPUU\|lKSzVyPUGuNVQ3QTRizszN	NXrpUmxXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
ES5	NVv4Vm1nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYXnWIxKUUN3ME2xMlE4OjR6IN88US=>	MkTMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
DEL	M37nc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MojyTWM2OD1zLkK1OFU4KM7:TR?=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
NB10	NVfsbmxoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MkDCTWM2OD1zLkOyOVU4KM7:TR?=	M{TEbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
NCI-H1581	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXPGXYZbUUN3ME2xMlM6ODR{IN88US=>	M130SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
D-566MG	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHPWO5dKSzVyPUGuOFA3QDNizszN	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
LXF-289	NXzrO5lRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmDuTWM2OD1zLkSzPVk3KM7:TR?=	M3O2cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
BT-549	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M17ZZ2lEPTB;MT61OlkxQSEQvF2=	NX;ZNIR4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
NKM-1	NUXUVI51T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MWHJR\|UxRTFwNkC1OVYh\|ryP	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
SW780	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHTKR3NKSzVyPUGuOlUyPThizszN	NIjlVIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
NCI-H292	NFHhOI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHXxT5JKSzVyPUGuOlY{QDNizszN	M4W4WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
HMV-II	M2LCO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHfrfXVKSzVyPUGuO\|A1QDhizszN	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
ALL-PO	MoPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVTJR\|UxRTFwOECwNVUh\|ryP	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
UACC-257	M4HPe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnKyTWM2OD1zLkiyNVY{KM7:TR?=	M2jDb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
PA-1	M4j6bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHLNO5FKSzVyPUGuPFI4OjVizszN	NGHmbJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
HD-MY-Z	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MYrJR\|UxRTFwOE[yPFEh\|ryP	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
HSC-4	MnW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MYXJR\|UxRTFwOUO4N\|kh\|ryP	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
GCT	NVmx[ZB1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3S2eGlEPTB;Mj6wNFkyPiEQvF2=	NX;xPWhWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
RT-112	NVHlbmIxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MlLtTWM2OD1{LkGzOFI1KM7:TR?=	NUfMPFl{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
A172	M1XZbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYPJR\|UxRTJwMUO2NFYh\|ryP	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
HCE-T	Mkj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnT3TWM2OD1{LkKwOVk5KM7:TR?=	M2j0OFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
YH-13	M2fxdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYDJR\|UxRTJwMkG2O\|Eh\|ryP	M3LqWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
DK-MG	M{X3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVXJR\|UxRTJwMkO4N\|Qh\|ryP	NVu0fmlCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
ACN	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MUPJR\|UxRTJwMkO4O\|Uh\|ryP	M37w[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
VA-ES-BJ	NX7YOVlsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYXJR\|UxRTJwMkS5OVch\|ryP	MkjtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
L-363	NYPyNG4zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFrHXHVKSzVyPUKuNlgxPjFizszN	NYPDRXo5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
HuH-7	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFHWOoVKSzVyPUKuOFIyPjVizszN	NHnBUIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
A4-Fuk	M1jhbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MmjuTWM2OD1{LkS3NVY5KM7:TR?=	M2nITVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
T-24	M{HrTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2DMXGlEPTB;Mj60PFA{PyEQvF2=	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
GOTO	M1PXT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUPDfoc{UUN3ME2yMlU{ODF\|IN88US=>	MnG1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
MV-4-11	NXG5bmtPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MkLUTWM2OD1{LkW5NVY6KM7:TR?=	MoC0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
DMS-114	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4XvWmlEPTB;Mj62OlM1PSEQvF2=	M1fxW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
MHH-NB-11	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MoHwTWM2OD1{LkewNlk6KM7:TR?=	NV;YS\|c3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
CHP-212	MniyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MkDDTWM2OD1{LkiyNFkyKM7:TR?=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
DMS-273	NUTGUm4yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUX1dmJTUUN3ME2yMlkxOjB5IN88US=>	M{\BR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
SF295	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFPFcpFKSzVyPUOuNFI2QTdizszN	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
NCI-H1563	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWH6S3ZoUUN3ME2zMlE2ODB3IN88US=>	NEfrS3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
NCI-H446	NV\xXIVvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUjpb2U6UUN3ME2zMlIzQDB3IN88US=>	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
HCC1806	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFrhUXNKSzVyPUOuNlc3PTdizszN	M{jjc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
SF126	MkPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NEnnU3RKSzVyPUOuN\|AxOTdizszN	NGjx[mE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
SW982	M3f3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M33hRmlEPTB;Mz6zN\|g4PSEQvF2=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
ES8	MoO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4fNWWlEPTB;Mz6zOFk6QSEQvF2=	NYTHfoJWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
SCC-4	NHXmVnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NW[x[ph6UUN3ME2zMlUxOzl4IN88US=>	M1;mO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
RPMI-8226	NXTxXYJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGPRXnZKSzVyPUOuOlI3OTZizszN	M{HXTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
EW-11	NF\aRlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Ml7zTWM2OD1\|Lk[zNFIzKM7:TR?=	NGPLNXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
COR-L105	NYK1SW9QT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MknYTWM2OD1\|Lk[zN\|M1KM7:TR?=	NHrEO4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
ES1	NV2zW3lFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXTJR\|UxRTNwOEOwPVQh\|ryP	NYHPNnpzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
KMOE-2	MmizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MmTnTWM2OD1\|LkmxPFA5KM7:TR?=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
ABC-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MX7JR\|UxRTNwOUO5NVEh\|ryP	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
NCI-H526	NGjFOXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUHJR\|UxRTNwOUmxNlYh\|ryP	M1y0WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
HCC1395	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NX7GWoxpUUN3ME2zMlk6PDh2IN88US=>	MorWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
DU-145	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MX\JR\|UxRTRwMUK4NlUh\|ryP	NET6WHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
JEG-3	NFq1TWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{LkOWlEPTB;ND6xOVkyPiEQvF2=	NFq5Wmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
HCC1187	NF\EfZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWTkdo5OUUN3ME20MlIyPTl5IN88US=>	M1\lNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
LC-2-ad	M3v3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnvsTWM2OD12LkKyNVc4KM7:TR?=	NIT3SZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
ONS-76	MlntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVzOVZZsUUN3ME20MlI1OTl{IN88US=>	NVnHS2F5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
CAL-27	NXG4VYdFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MV;JR\|UxRTRwMkSzOFQh\|ryP	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
8-MG-BA	M3G2W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1W0S2lEPTB;ND6yOlY2QCEQvF2=	M2jSRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
HGC-27	NF\VR3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXvtfoRwUUN3ME20MlI6PjZizszN	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
Hs-578-T	MkCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MkfxTWM2OD12LkOxOFY5KM7:TR?=	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
EW-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1raZmlEPTB;ND61N\|AyPCEQvF2=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
SW1573	NHfIXGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Ml3tTWM2OD12LkW1NVY{KM7:TR?=	NWrI[oNmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
SNU-423	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFXPO5RKSzVyPUSuOlA4QSEQvF2=	NEexb2w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
HOS	NWLVXokxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MWrJR\|UxRTRwNkm3O{DPxE1?	MorQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
LB1047-RCC	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MUPJR\|UxRTRwOEG0NVgh\|ryP	M3nYXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
ChaGo-K-1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVXJR\|UxRTRwOEmwOFgh\|ryP	Mn\jQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
A3-KAW	M1e1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1LWTmlEPTB;ND65O\|M2OiEQvF2=	M4fCTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
CAS-1	MmTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NULzPI9RUUN3ME20Mlk6QTB6IN88US=>	Mn\FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
NBsusSR	NWfLV3p5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYrJR\|UxRTVwMEO1NVQh\|ryP	M2rYWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
KM12	NH7iflBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{DBRmlEPTB;NT6yPVgzPyEQvF2=	NEK0Znc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
NCI-H1155	NX3pPWN5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUPJR\|UxRTVwM{ixPFUh\|ryP	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
EFM-19	M2LBd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUXJR\|UxRTVwNEG3N\|ch\|ryP	NXjxN2RyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
D-392MG	M4OzZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVHJR\|UxRTVwNUe4OFkh\|ryP	NYrXe21IRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
JVM-3	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MV3JR\|UxRTVwN{KzNlUh\|ryP	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
EW-16	NUOwWZl7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Ml22TWM2OD13Lke1OVg{KM7:TR?=	NVjaO3pRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
KARPAS-45	M1XPfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVW5SXdnUUN3ME21Mlg1OzJ3IN88US=>	NWXzOWJ5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
NCI-H28	NH;RZmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmP3TWM2OD13Lki3PVE5KM7:TR?=	M2mxRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
COLO-829	M3PYc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2LJT2lEPTB;NT65NVUxPCEQvF2=	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
KM-H2	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVGyPYpCUUN3ME21MlkzOzl3IN88US=>	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
NCI-H82	M1XU[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MmPaTWM2OD13LkmyO\|cyKM7:TR?=	M{fPSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
OAW-42	NIe1SnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NX2zb5RFUUN3ME21Mlk5QDJzIN88US=>	NWPoXpB{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
A704	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFflUVVKSzVyPU[uNVA2PzRizszN	NHf6TYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
NCI-H1048	NVjSVoJLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mlz2TWM2OD14LkGwOVk6KM7:TR?=	NFy5TIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
LOXIMVI	NXzpeXY5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGPGUHBKSzVyPU[uNVEzPDhizszN	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
MKN45	MoPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MkK4TWM2OD14LkK2NFE3KM7:TR?=	NIHTRXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
D-502MG	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NULBTW9tUUN3ME22MlI5QDV5IN88US=>	NFnPeYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
HUTU-80	NXLk[JFRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXm3fGU3UUN3ME22MlQyPjh6IN88US=>	M1z1dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
S-117	NHfDUnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NH7SVWFKSzVyPU[uOVAzPjdizszN	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
HCC1569	MkSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHj3ZpdKSzVyPU[uOVM4OzdizszN	M{DYNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
J-RT3-T3-5	M4L3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MULJR\|UxRTZwNUS1O\|Ih\|ryP	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
OC-314	NVm3UI0xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MV\JR\|UxRTZwOUGxOVkh\|ryP	MonZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
SNU-449	NVfVdG1mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MlL4TWM2OD15LkCxNFczKM7:TR?=	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
NCI-H720	Mn61S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MmfHTWM2OD15LkG5N\|Q2KM7:TR?=	Mmj6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
KP-N-YS	NGHCO4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NV\RdYNQUUN3ME23MlIxPzJizszN	MoK3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
IGROV-1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NF3BZ5NKSzVyPUeuN\|I{QDZizszN	NYfDRYZuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
SK-PN-DW	MoTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NWPNbG5pUUN3ME23MlQ5OTVizszN	NWfNR2g4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
HCC1419	M{HOT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYnBXVYzUUN3ME23MlU{KM7:TR?=	Mo\xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
HAL-01	NF63cm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWnJR\|UxRTdwNkC2OFQh\|ryP	NV\C[ohIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
HCC2998	MlX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{XIPWlEPTB;Nz62NFc1OyEQvF2=	NVLHRY04RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
SK-N-FI	NGDT[lBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M33IR2lEPTB;Nz62N\|A{OyEQvF2=	NWmxcmEyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
GI-ME-N	NVXVTXJuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MlvBTWM2OD15Lk[0PVM1KM7:TR?=	M{G2U\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
SW1088	MnLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MmWwTWM2OD15Lk[1PFI3KM7:TR?=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
IA-LM	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NW\vNYQzUUN3ME23MlY5PjF\|IN88US=>	MmDLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
SK-NEP-1	MkHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MkfXTWM2OD15Lk[5OlEh\|ryP	NWHMd2hDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
MDA-MB-415	NFHTd2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUjEdHd4UUN3ME23Mlg6OTh4IN88US=>	M3LSb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
COLO-800	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXrXTXhqUUN3ME23Mlk1PDl{IN88US=>	MljUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
NCI-H2228	NWCzPZlZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NG\aNldKSzVyPUiuNVU4QDNizszN	NYeweJBDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
D-423MG	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{T3NGlEPTB;OD6yNVczKM7:TR?=	Ml7jQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
TE-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlL0TWM2OD16LkS0N\|E3KM7:TR?=	NYLZXlZ5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
NOS-1	MoGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NIC2XJhKSzVyPUiuOVE2OzRizszN	MmLhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
8505C	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NG\veYJKSzVyPUiuOlQ5OjRizszN	NITTS3M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
HEC-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NX32SWl6UUN3ME24Mlc5PDN7IN88US=>	M2jkVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
TE-11	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MYfJR\|UxRThwOUm1OVEh\|ryP	Mlv1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
CTB-1	Mn7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NF3lXVlKSzVyPUmuNFE1OzNizszN	M2L5VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
TGBC11TKB	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFfLeolKSzVyPUmuNFIzPDFizszN	NV6ycWl{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
NB17	NXnVb2I4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWTFZZJsUUN3ME25MlE5QDdizszN	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
Becker	MkLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NW\2dHAzUUN3ME25MlQyQTR2IN88US=>	MlvOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
SN12C	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2G2c2lEPTB;OT60OVI{PCEQvF2=	NEf6Slk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
COLO-320-HSR	NEnFOIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mnm2TWM2OD17Lk[wNlM4KM7:TR?=	MlrCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
D-283MED	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MYrJR\|UxRTlwNkOwO\|Ih\|ryP	MmPvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
D-263MG	NF\SRVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Moj5TWM2OD17LkizN\|g1KM7:TR?=	NUDrVYozRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
MEL-JUSO	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NIrlT4ZKSzVyPUmuPVAyOjdizszN	NGrqOVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
T98G	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MmO1TWM2OD17LkmwNlA{KM7:TR?=	Mk\nQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
HLE	NH:4XZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXHsWVh6UUN3ME25MlkxQTB7IN88US=>	NITTTnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
Ca9-22	M13UO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{P3eGlEPTB;MUCuNFY3PSEQvF2=	M1izcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
OS-RC-2	NHLqfXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVjBbYpwUUN3ME2xNE4yODR3IN88US=>	NH;pTnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
T47D	M1HNUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGW3e4ZKSzVyPUGwMlE2PSEQvF2=	NIP2PYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
GI-1	MlnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGf4XnFKSzVyPUGwMlM2OzNizszN	M3;qUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
NUGC-3	NFvkeYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHu3VFVKSzVyPUGwMlQ1ODJizszN	NFzl[209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
MDA-MB-361	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NX\iRYhTUUN3ME2xNE41PDN{IN88US=>	M3PoVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
SCC-15	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlPoTWM2OD1zMD60O\|E5KM7:TR?=	NVH2PG5nRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
KS-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NYG2ZYo2UUN3ME2xNE43OzBzIN88US=>	NWewZXFvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
CAL-12T	NGTZcnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MkD5TWM2OD1zMD62N\|YyKM7:TR?=	MmKzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
OVCAR-4	NVzHT2d6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MX7JR\|UxRTFyLkewOlgh\|ryP	NV34[pdmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
HuP-T4	NIW0dHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3\uXGlEPTB;MUGuNFMzQCEQvF2=	NYWyXZMxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
NCI-H358	Mkm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFPhR5pKSzVyPUGxMlI3PTdizszN	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
HO-1-N-1	MmrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MkfiTWM2OD1zMT6zN\|k5KM7:TR?=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
NH-12	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{H5cWlEPTB;MUGuOVM4QCEQvF2=	NX3E[pZsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
MOLT-4	M2DrUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3LBcGlEPTB;MUGuOVk5PSEQvF2=	MnLZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
K-562	NW\OTnVbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUPJR\|UxRTFzLkeyOFgh\|ryP	NFzPZ3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
ES6	Mn60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVPJR\|UxRTFzLki1PFEh\|ryP	M3fjSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
RO82-W-1	NXj1eY12T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NH7FZ25KSzVyPUGxMlkxPjRizszN	NGG2NJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
Ramos-2G6-4C10	MkftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NWfP[\|l7UUN3ME2xNU46OzJizszN	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
23132-87	Mn7qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MmLDTWM2OD1zMj6wPFIyKM7:TR?=	M2f4S\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
A549	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MUTJR\|UxRTF{LkOyPFUh\|ryP	NI\WSFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
NCI-H23	NIj6OHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{L0dGlEPTB;MUKuOVAzPiEQvF2=	M3PVXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
H9	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlTiTWM2OD1zMj61OVc4KM7:TR?=	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
LB771-HNC	NEPF[4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXHJR\|UxRTF{Lke2OUDPxE1?	M4m2eFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
QIMR-WIL	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXX4RodIUUN3ME2xNk45OjV6IN88US=>	NX[yO5FnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
HSC-3	NX3qUG1xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Ml;FTWM2OD1zMj65Nlc3KM7:TR?=	NHzqUpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
PFSK-1	NYW1PXZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M324PWlEPTB;MUKuPVUxPyEQvF2=	M1nJelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
ETK-1	NIjofIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2LCO2lEPTB;MUOuNFc4QSEQvF2=	MoPvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
SW1710	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWTJR\|UxRTF\|LkO2OFEh\|ryP	MlvvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
COLO-684	MmTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFTWeXFKSzVyPUGzMlQ2PDFizszN	MnK0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
RPMI-7951	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MX;JR\|UxRTF\|LkWxN\|Yh\|ryP	Mn\LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
A101D	NFHnW4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mk\YTWM2OD1zMz61N\|Q6KM7:TR?=	M{X2[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
KE-37	NIj6dmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2nQe2lEPTB;MUOuOVg5PyEQvF2=	NXj2NGx3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
SiHa	M{DFRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NITXXlZKSzVyPUGzMlg{PDZizszN	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
NCI-H226	MliyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NX\sXm9vUUN3ME2xN{45QDB6IN88US=>	MnrKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
DB	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1jGUmlEPTB;MUOuPVkzQCEQvF2=	NXfjcXlURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
HT-1197	NIDCc4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFLhPVFKSzVyPUG0MlA5ODlizszN	MljJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
SBC-5	NYrBTmxDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Ml3DTWM2OD1zND6xN\|YzKM7:TR?=	NFruSnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
VMRC-RCZ	NImxO5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWrQOJJNUUN3ME2xOE42Pzd2IN88US=>	M4HwW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
697	M4XlZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NX7heXhlUUN3ME2xOE43OjdizszN	NWO4PGVORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
OMC-1	NIG0b41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NY\K[\|lTUUN3ME2xOE44QDh6IN88US=>	NXLWXlNSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
SKG-IIIa	NWmwSnI{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWPIS442UUN3ME2xOE45ODBzIN88US=>	M2HwNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
DOK	NIf1WlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVzib2NlUUN3ME2xOE46QTN\|IN88US=>	MmHSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
NCI-H2029	M3LPcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXzJR\|UxRTF3LkO2NFIh\|ryP	NXj5V3RzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
NCI-H2009	NX7SSJNkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVr3SGNOUUN3ME2xOU42ODl3IN88US=>	NXH6[ZdZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
LK-2	MoPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWnJR\|UxRTF3Lk[0OFkh\|ryP	M4nW[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
NCI-H661	M3fOVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mnq3TWM2OD1zNT65NFc2KM7:TR?=	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
GT3TKB	NFnKWWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3rJUmlEPTB;MU[uNFY4PiEQvF2=	M3vkZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
GP5d	NUK0R4RNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MkPUTWM2OD1zNj6zOFIh\|ryP	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
SK-MEL-2	NGHSO2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVXJR\|UxRTF4LkS0PFUh\|ryP	M4DUVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
SK-UT-1	M1zhSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXnJR\|UxRTF4LkW2OUDPxE1?	NVjjSYJ[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
NB7	M13PUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MU\JR\|UxRTF4Lk[5O\|Eh\|ryP	MnnoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
NCI-H460	M1LaeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4PKUmlEPTB;MU[uO\|MzPiEQvF2=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
8305C	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NF2yO5RKSzVyPUG2Mlc5PzdizszN	Mk\xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
CaR-1	M{jQSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVTJR\|UxRTF4LkixNVEh\|ryP	M{[3[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
D-247MG	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1\hcmlEPTB;MU[uPFYzPSEQvF2=	NIPGTmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
LoVo	M2\YR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Ml3lTWM2OD1zNj65OFg5KM7:TR?=	M4jVOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
NCI-H2405	NIHHe3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NIjNOZpKSzVyPUG3MlE6ODhizszN	Ml;HQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
AU565	MkXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVHBbHNpUUN3ME2xO{4zOjVizszN	NXO3VYZbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
OCI-AML2	NHTCbmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVvmW4UxUUN3ME2xO{42OzF5IN88US=>	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
22RV1	NVTkd3FCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MV;JR\|UxRTF5LkW4PFQh\|ryP	M4jSN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
HT-144	NIj2TpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUTJR\|UxRTF5Lk[1PVgh\|ryP	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
HuO9	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWjNSplwUUN3ME2xO{44ODNzIN88US=>	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
Daoy	MmnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVK5fGVNUUN3ME2xO{44OTh2IN88US=>	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
SJRH30	NXOwOY9pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnTsTWM2OD1zNz64OFg6KM7:TR?=	M3juclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
CHL-1	Ml6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mnv4TWM2OD1zNz65NlQ6KM7:TR?=	MnTNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
J82	NUXPZ4YyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MkL0TWM2OD1zNz65OlM2KM7:TR?=	NIHLUYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
COR-L23	M1;lTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NY\qWJNvUUN3ME2xPE4xODFzIN88US=>	Mk\kQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
SNU-C2B	NIDuWnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MkD1TWM2OD1zOD6yNlc3KM7:TR?=	MnfoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
NCI-H1770	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1zjV2lEPTB;MUiuOFYyPSEQvF2=	NETWPYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
MHH-PREB-1	M3i0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGjvSI9KSzVyPUG4MlU3QTdizszN	NUnrO5p4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
ES3	Ml3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MYfJR\|UxRTF6LkW4PFMh\|ryP	M3XjUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
MDA-MB-231	NGfLPGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NILqVHdKSzVyPUG4MlY2ODJizszN	Ml7VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
MN-60	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHTqboVKSzVyPUG5MlA2QTJizszN	M2fPbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
EPLC-272H	NEDENGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1TzSmlEPTB;MUmuN\|cxQCEQvF2=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
SW948	NGDJcXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mn63TWM2OD1zOT6zPVM1KM7:TR?=	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
MOLT-13	NH;vZYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHXkVVdKSzVyPUG5MlQ2PDZizszN	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
HL-60	M1TPZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUftVnlYUUN3ME2yNE4zOTRzIN88US=>	MlmzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
CP50-MEL-B	NYDDRm5NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4jsUWlEPTB;MkCuOFc1QCEQvF2=	NGnGZmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
NTERA-S-cl-D1	M{TuR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NI\rO4FKSzVyPUKwMlQ6PzhizszN	M{Lsb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
KINGS-1	MmDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYiwV29KUUN3ME2yNE44QTZ5IN88US=>	MmXBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
DOHH-2	MmPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NUW2[FQyUUN3ME2yNE46ODZizszN	NUH6NYhmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
BB65-RCC	NEX0SnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MV3JR\|UxRTJyLkmyPFUh\|ryP	M4XURlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
NB12	NYXIOohbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MkDXTWM2OD1{MT6wN\|k1KM7:TR?=	NVi5NVg1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
KY821	M1riUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MV3JR\|UxRTJzLkW4NkDPxE1?	NFrvcY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
PSN1	NF7h[3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3j2b2lEPTB;MkGuOlQ2OyEQvF2=	Mlf5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
EGI-1	M1S1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2jHXmlEPTB;MkGuO\|Q2PCEQvF2=	MlvtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
CTV-1	NVTHVINPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4DzbmlEPTB;MkKuN\|A{OSEQvF2=	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
TI-73	NX\tT3pnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnjDTWM2OD1{Mj6zOFk5KM7:TR?=	Mmf3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
LCLC-103H	NFjtZYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1nRcWlEPTB;MkKuOFc2OiEQvF2=	NIHsOoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
D-542MG	M2LPdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MV;JR\|UxRTJ{LkW1OVgh\|ryP	NEfzOII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
ATN-1	MnroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFjucWNKSzVyPUKyMlY1OzlizszN	NFzrWY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
SK-MEL-1	MlfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NWH4[mRKUUN3ME2yNk45OzZ6IN88US=>	MmO2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
HDLM-2	MnjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{XSR2lEPTB;MkOuNVQ4QCEQvF2=	NG\TdlI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
UM-UC-3	MkfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2S2[WlEPTB;MkOuNVk1PCEQvF2=	M1Tu[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
NCI-H1573	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGLC[IlKSzVyPUKzMlQ3QDFizszN	NUHBcYhmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
NCI-H520	M2TReWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUG5V28{UUN3ME2yN{41QTR6IN88US=>	M1nTdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
ESS-1	M4DGVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVPJR\|UxRTJ\|LkiwOVkh\|ryP	M1jHRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
COR-L88	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWrJR\|UxRTJ\|Lkm0O\|Uh\|ryP	M4TPfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
TGBC24TKB	Mnr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MX3JR\|UxRTJ2LkCzNVIh\|ryP	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
HCC1937	NYPWVoNJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3fSXWlEPTB;MkSuNUDPxE1?	M33SO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
RS4-11	NIj4WYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGH4WJJKSzVyPUK0MlE1OiEQvF2=	MmPoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
HCC38	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NIfqPZlKSzVyPUK0MlI{QTRizszN	MmL0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
RPMI-2650	NHXnbHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHjZVXdKSzVyPUK0MlYyPjJizszN	NWPiOFYxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
P12-ICHIKAWA	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWLJR\|UxRTJ2Lk[yOVgh\|ryP	MoTYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
YAPC	NILDWI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHvlVWFKSzVyPUK0MlgzOTRizszN	M4rxdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
NB13	NYfWdoJZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NH24ZnJKSzVyPUK1MlI3OTFizszN	M4G5NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
SK-N-AS	Ml3xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXnJR\|UxRTJ3Lki1PFQh\|ryP	NHzKUHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
SK-N-DZ	M{\2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NEXERmVKSzVyPUK2MlA1QSEQvF2=	NYjFUnZSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
LS-411N	NG\PNW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NV;I[FV7UUN3ME2yOk4zODN6IN88US=>	M4fNd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
NCI-H810	MkjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NH\kO41KSzVyPUK2MlMyOTJizszN	NGfKNmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
NCI-SNU-1	NGjPXINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVvPcZM4UUN3ME2yOk42PDV2IN88US=>	NGPPOmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
HH	Mkm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYDCNGdrUUN3ME2yOk42PTJ7IN88US=>	NVPsfY5HRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
U-2-OS	Mn;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NITwUHNKSzVyPUK2Mlc{QDJizszN	Ml\lQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
SF539	M4LQU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYLJR\|UxRTJ4LkiwNVgh\|ryP	NHvPe2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
NCI-H2052	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MXrJR\|UxRTJ5LkC4OkDPxE1?	M4LCcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
A673	NVXseJo4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmfVTWM2OD1{Nz6yNVAzKM7:TR?=	NHjBOoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
WM-115	MmTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MmH1TWM2OD1{Nz63O\|Y4KM7:TR?=	M{TUO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
SW48	NH\DTlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NF3wRoFKSzVyPUK3MlgxODVizszN	NHu1b4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
NOMO-1	M4jacWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NH70PVRKSzVyPUK3Mlg2OzJizszN	M1qycFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
PC-3	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3XJb2lEPTB;MkeuPFk1OSEQvF2=	M2Dq[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
UMC-11	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWDRPJdIUUN3ME2yO{46OzR\|IN88US=>	NUXQW25KRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
U-118-MG	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3z6TWlEPTB;MkiuNFEzOyEQvF2=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
NCI-H2452	M3G3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXPJR\|UxRTJ6LkC4NlIh\|ryP	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
CAMA-1	NXuxbJNkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NEDtfHVKSzVyPUK4Mlg2PjRizszN	Mk\OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
MC-IXC	NHfJd5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NI\qUnlKSzVyPUK5MlI{PjZizszN	NHXNPXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
ES4	M1rUXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{jlZWlEPTB;MkmuN\|E4OiEQvF2=	NXXLTGVDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
BHT-101	M{\HT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MV3JR\|UxRTJ7LkOyNUDPxE1?	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
KP-4	M1G2c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MlvkTWM2OD1{OT61NVYh\|ryP	M2C0WlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
CAL-54	NHzWdYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1v5W2lEPTB;MkmuOVQ1PSEQvF2=	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
5637	MlXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWfJR\|UxRTJ7Lk[0NlEh\|ryP	M4jiXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
MOLT-16	NIi3[lBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWfJR\|UxRTJ7LkeyOlkh\|ryP	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
Ca-Ski	NXXmV3R7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{XFOWlEPTB;MkmuPVQ3KM7:TR?=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
AsPC-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MXnJR\|UxRTNyLkCyNVIh\|ryP	MoixQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
MSTO-211H	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4fScWlEPTB;M{CuNVUh\|ryP	NHr3cGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
L-428	NGLnflVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVXJR\|UxRTNyLkSwOUDPxE1?	NXXuTpZERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
SW1463	M1zGO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NF20OXZKSzVyPUOwMlU{QDNizszN	Mk\QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
NCI-H1648	NY\xT5Z4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3Wz[GlEPTB;M{CuOVU4PCEQvF2=	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
CAKI-1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUHpbpI5UUN3ME2zNE44PzB{IN88US=>	NV32RoVnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
YKG-1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1jXTmlEPTB;M{GuNFI3OyEQvF2=	M17SRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
A2058	M1fFfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NE\aSHVKSzVyPUOxMlEyPjRizszN	M36yPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
A375	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1i4bWlEPTB;M{GuNVY6PiEQvF2=	NIf1[2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
SNB75	NVr5c\|BMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGLNdWRKSzVyPUOxMlI1OzVizszN	NFPDZ249[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
SK-HEP-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3ywNmlEPTB;M{GuOFI4OSEQvF2=	M2H3[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
ME-180	M{D5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MY\JR\|UxRTNzLk[1OFIh\|ryP	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
NCI-H209	MoH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVziUXRSUUN3ME2zNU45OjR5IN88US=>	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
HC-1	NVn4TZZwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MU\JR\|UxRTN{LkG0OFYh\|ryP	NX;PU2dNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
LB373-MEL-D	NVPG[XJuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MoP1TWM2OD1\|Mj6xPVcyKM7:TR?=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
SNU-387	NUD5WlZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4rsdWlEPTB;M{KuN\|E6OSEQvF2=	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
C32	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnezTWM2OD1\|Mj6zN\|U{KM7:TR?=	M3H4NFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
EW-13	MkT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3\hcGlEPTB;M{KuPVQxQCEQvF2=	NVPLWoxzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
BFTC-905	MoL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHXaU4tKSzVyPUOzMlUyOzZizszN	MkG1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
NCI-H1299	NVfSXItYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYXJR\|UxRTN\|LkW2NlEh\|ryP	MnjPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
LU-135	NGXJ[YFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NI[3[XFKSzVyPUOzMlgxOSEQvF2=	NHfDPYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
NCI-H2122	M2q3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVuzPWxMUUN3ME2zN{46QTZ4IN88US=>	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
SK-LMS-1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3PIZWlEPTB;M{SuOFExPyEQvF2=	MlvmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
LNCaP-Clone-FGC	NHvKdGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NEjoeHFKSzVyPUO0Mlg2OTVizszN	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
NCI-H1092	MmfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MknoTWM2OD1\|NT6yO\|Q4KM7:TR?=	M2Lkd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
MS-1	NEfuOFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NICwd2ZKSzVyPUO1MlMxOzhizszN	NUe4TndtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
KYSE-510	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NYfnU3lWUUN3ME2zOU42ODR{IN88US=>	MkTQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
NCI-H1793	NGnKcZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mn2xTWM2OD1\|NT62OVQ2KM7:TR?=	NUHJeIRFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
MIA-PaCa-2	NX:xOlZxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Ml;rTWM2OD1\|Nj6wOFk3KM7:TR?=	MnjIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
EW-22	MmfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVvJR\|UxRTN4LkSwO\|Ih\|ryP	NYCyUHJsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
IGR-1	NIjabGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFjPRYFKSzVyPUO2MlgyQDRizszN	M3HZR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
HT-1080	NXvj[5NrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFfPcIhKSzVyPUO3MlEzPSEQvF2=	NInOdnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
M14	NVizRXNHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2HtTGlEPTB;M{euNVY1OiEQvF2=	NGHVbnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
786-0	M{LJPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MlXTTWM2OD1\|Nz6yO\|k1KM7:TR?=	NGnHV3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
MZ2-MEL	MkHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3KwXGlEPTB;M{euOFUxOSEQvF2=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
NCI-H510A	NED4bXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlPxTWM2OD1\|Nz65OFEzKM7:TR?=	NETGbo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
LAN-6	NUe5TIp3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFr6NZFKSzVyPUO3Mlk2QDJizszN	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
SW620	NXzCRoRDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{DnNGlEPTB;M{iuOFk4PCEQvF2=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
LB2241-RCC	MnfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MlPITWM2OD1\|OT64NlA2KM7:TR?=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
Detroit562	MoD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYD6T\|JwUUN3ME20NE4yOjZ6IN88US=>	MlLDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
HN	M2PRO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUHJR\|UxRTRyLkG3PFIh\|ryP	NWnk[GRORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
HCT-15	NFyw[IpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnnjTWM2OD12MD61PVA4KM7:TR?=	NIT1dVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
C2BBe1	NHzvPYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1i0cGlEPTB;NECuPVE2PyEQvF2=	MnnUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
A498	M4fOcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGD2fGFKSzVyPUSxMlMxOTVizszN	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
SK-MEL-24	MnPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2fNbGlEPTB;NEGuOFczPSEQvF2=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
OVCAR-5	Mn6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NIW1XmFKSzVyPUSxMlc4PjdizszN	MkT4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
NCI-H1792	NFTIWYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3\hNWlEPTB;NEGuPVgzOSEQvF2=	M2rx[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
KOSC-2	NVzONXBET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4L5W2lEPTB;NEKuNlY6QSEQvF2=	M4ji[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
Mo-T	NE\FendIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnuxTWM2OD12Mj64PVU5KM7:TR?=	M4rsc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
CFPAC-1	NHTybZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnrxTWM2OD12Mz60PVQ1KM7:TR?=	Mn7XQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
CAL-51	M1r2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1TqTmlEPTB;NEOuOVYxPSEQvF2=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
RH-18	NEnicJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmT3TWM2OD12Mz64NFUh\|ryP	M{TjNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
EC-GI-10	Ml7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NUXje4l{UUN3ME20N{45OzR5IN88US=>	M4jSTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
HSC-2	M3;5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXPz[ndzUUN3ME20OE4xODlizszN	NELvXJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
ML-2	NWfXVXFqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1\pR2lEPTB;NEWuNlYzOSEQvF2=	M3LicFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
KNS-81-FD	NIC4S5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4jjUWlEPTB;NEWuO\|M3PSEQvF2=	MlvnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
NB6	M4LwcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYPJR\|UxRTR4LkGxNUDPxE1?	M2O4clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
MCF7	Ml6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2Tw[GlEPTB;NE[uOVU{OyEQvF2=	Moj5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
P30-OHK	M2\pXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NF3XWlVKSzVyPUS2MlgyOTdizszN	M2\oS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
BPH-1	NXy4[5pZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MWPJR\|UxRTR4Lkm4NFUh\|ryP	NYrZV5dsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
U251	NX2x[HhwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYrJR\|UxRTR4Lkm5OEDPxE1?	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
MKN1	NV\pR41IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2\3emlEPTB;NEeuOVE{PyEQvF2=	NV3VOG9jRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
A431	NXHRc4dYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUDwXGRkUUN3ME20O{45OzN6IN88US=>	NH;Ve3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjh7OUK2M{c,W0GQR1XSQE9iRg>?
C8166	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MXfJR\|UxRTR7LkKwN\|kh\|ryP	MnL2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
HEL	M2DxRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MWfJR\|UxRTR7LkSwOlQh\|ryP	M2\VSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzQDl7Mk[vK\|5USU6JRWK8M4E,
RMG-I	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVrERYhYUUN3ME20PU41PDR2IN88US=>	Mm\KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQnNCVkeHUkyvZV4>
CAL-72	M1n5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{P0XWlEPTB;NEmuOlA4PSEQvF2=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+V2FPT0WUPD;hQi=>
SW962	NVvUNZlvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NIjsPVFKSzVyPUS5Mlk{OzJizszN	NYG5ZlRXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRlODTlfFVlww[T5?
MCF7	NIP1UGJCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=	M{H6TlUh\GG7cx?=	M1nZPWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC1JIRigXNiYomgV3JDKGG\|c3H5MEBIUTVyIE2gNE46PyEQvF2u	MkPXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6Mkm1OFkoRjJ\|OEK5OVQ6RC:jPh?=
MDA-MB-468	M1:5dGFvfGmycn;sbYZmemG2aY\lJIF{e2G7	MoHVOUBl[Xm\|	MX3BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2GQT3NRk01PjhiY3XscJMh[XO\|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPSCmYYnzJIJ6KFOUQjDhd5NigSxiR1m1NEA:KDFwMzFOwG0v	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh{OUW0PUc,OjN6Mkm1OFk9N2F-
HCC1954	NWL3c5pESW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=	NITuUGo2KGSjeYO=	M{LB[mFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPDNVk2PCClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA2KGSjeYOgZpkhW1KEIHHzd4F6NCCJSUWwJF0hOi55IN88UU4>	MnfjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6Mkm1OFkoRjJ\|OEK5OVQ6RC:jPh?=
SKBR3	NXHvUYZ4SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=	M2HVTVUh\GG7cx?=	MU\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFONQmKzJINmdGy\|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEWg[IF6eyCkeTDTVmIh[XO\|YYmsJGdKPTBiPTCzMlgh\|ryPLh?=	NXjYb3dmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4Nlk2PDlpPkKzPFI6PTR7PD;hQi=>
MDA-MB-231	MoPlRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?	NWDvc3R2PSCmYYnz	M4HxcmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVTBMW1DNTJ\|MTDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB3IHThfZMh[nliU2LCJIF{e2G7LDDHTVUxKD1iNz6zJO69VS5?	NUXyTHJ[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4Nlk2PDlpPkKzPFI6PTR7PD;hQi=>
MCF7	NE[weYhEgXSxdH;4bYNqfHliYYPzZZk>	NEjaVYc2KGSjeYO=	NXyyS445S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCjZoTldkA2KGSjeYOgZpkhW1KEIHHzd4F6NCCJSUWwJF0hOi5\|IN88UU4>	NX;YSpZZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4Olc1ODNpPkK0PFY4PDB\|PD;hQi=>
MDA-MB-468	MkXhR5l1d3SxeHnjbZR6KGG\|c3H5	M1niW\|Uh\GG7cx?=	NInqT41EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtOFY5KGOnbHzzJIFnfGW{IEWg[IF6eyCkeTDTVmIh[XO\|YYmsJGdKPTBiPTCyMlgh\|ryPLh?=	MlHNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6Nke0NFMoRjJ2OE[3OFA{RC:jPh?=
SKBR3	NWfZeGxbS3m2b4TvfIlkcXS7IHHzd4F6	MXS1JIRigXN?	MWLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTT2JTOyClZXzsd{Bi\nSncjC1JIRigXNiYomgV3JDKGG\|c3H5MEBIUTVyIE2gOE43KM7:TT6=	NY\MUoI6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4Olc1ODNpPkK0PFY4PDB\|PD;hQi=>
MDA-MB-231	M4S5b2N6fG:2b4jpZ4l1gSCjc4PhfS=>	MXe1JIRigXN?	MmDrR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDh[pRmeiB3IHThfZMh[nliU2LCJIF{e2G7LDDHTVUxKD1iMUGg{txONg>?	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh4N{SwN{c,OjR6Nke0NFM9N2F-
Saos-2	NFPrPXFyUFSVIHHzd4F6		MXLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW2Gxcz2yJINmdGy\|	NY\qTpE2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-12	NEK1XGtyUFSVIHHzd4F6		NW\XeG57eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFLUMVEzKGOnbHzz	NGPmdJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
OHS-50	M{\PcpFJXFNiYYPzZZk>		M2XES5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SJ-GBM2	MmjQdWhVWyCjc4PhfS=>		MoTtdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOMLVfCUVIh[2WubIO=	NGT5bG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-MC	NVLrbmZreUiWUzDhd5NigQ>?		M2XMdZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz	M1vBSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1	NFTUT45yUFSVIHHzd4F6		MnHZdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6ELVXCZ\|Eh[2WubIO=	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh18	MkSwdWhVWyCjc4PhfS=>		MoG5dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqMUigZ4VtdHN?	M1nveVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
HUVEC	NHfPVlFCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=	M1LnTVEhcHJ?	MVPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IG\FS2Yue3SrbYXsZZRm\CCKVW\FR{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkheHKnaX7jeYJifGWmIH\vdkAyKGi{IH\vcIxwf2WmIHL5JIFl\Gm2aX;uJI9nKF[HR1[gcYVie3W{ZXSgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNFAxPSEQvF2u	Mkj4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI5QTl{Nj:nQmNpTU2ETEyvZV4>
HUVEC	MYPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?	MkixNUBpeg>?	MlnrRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDWSWdHNXO2aX31cIF1\WRiSGXWSWMh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KHC{ZXnuZ5Vj[XSnZDDmc5IhOSCqcjDmc4xtd3enZDDifUBi\GSrdHnvckBw\iCYRVfGJI1m[XO3cnXkJIFnfGW{IEeyJIhzeyCrbjDwdoV{\W6lZTDv[kBidGK3bXnuJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMECyO{DPxE1w	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+R4hGVUKOPD;hQi=>
A549	M1u2emFvfGmycn;sbYZmemG2aY\lJIF{e2G7	NWD0S3ZjPDhiaILz	NXX6RVIySW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBXTUeILYP0bY12dGG2ZXSgbJVu[W5iQUW0PUBk\WyuczDh[pRmeiB2ODDodpMh[nliQ1PLPEBie3OjeTygTWM2OCB;IEKyMlQh\|ryPLh?=	NY\tc21IRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ6OUmyOk8oRkOqRV3CUFww[T5?
HepG2	MX7BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?	MVW0PEBpenN?	NX7MfGZOSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBXTUeILYP0bY12dGG2ZXSgbJVu[W5iSHXwS\|Ih[2WubIOgZYZ1\XJiNEigbJJ{KGK7IFPDT\|gh[XO\|YYmsJGlEPTBiPTCzPE44KM7:TT6=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlg6QTJ4Lze+R4hGVUKOPD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-c-kit / c-kit / p-AKT / AKT / p-ERK / ERK / p-STAT3 / STAT3 / p-STAT5 / STAT5 / p-S6K / S6K / p-S6 / S6; PubMed: 31205508 Ther Adv Med Oncol Immunoblotting analysis of indicated proteins in c-KIT mediated signaling pathways of GIST-T1, GIST-882, GIST-48B, and GIST-5R cell lines. PARP / cleaved PARP / caspase-3 / cleaved caspase-3; PubMed: 31205508 Ther Adv Med Oncol Immunoblotting analysis of apoptosis-related proteins after axitinib treatment in human GIST cell lines. Imatinib and sunitinib were used as positive controls.	31205508
Immunofluorescence	alpha-tubulin; PubMed: 26474283 Oncotarget Representative images of RCC cells treated as above described, and then immunostained with anti-α-tubulin antibody. Bar: 50 μM	26474283
Growth inhibition assay	Cell viability ; PubMed: 26474283 Oncotarget A. A-498 and Caki-2 RCC cell lines were cultured up to 96 h with different doses of axitinib. Cell viability was determined by MTT assay. Data shown are expressed as mean ± SD of three separate experiments; *p < 0.01 vs vehicle-treated cells. B. RCC cell 䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ⟸෕䐺痖暼瘿⟸෕ᾰƌ ⟸෕Ð㺣痖⟸෕	26474283

In vivo

Axitinib exhibits primary inhibition to orthotopically transplanted models such as M24met (melanoma), HCT-116 (colorectal cancer), and SN12C (renal cell carcinoma). ^[1] Axitinib delays the tumor growth with 11.4 days compared to the controls (p.o. 30 mg/kg) and decreases the Mean Vessels Density (MVD) to 21, compared to 49 in controls, in IGR-N91 ﬂank xenografts. ^[2] Axitinib significantly inhibits growth and disrupts tumor microvasculature in BT474 breast cancer model at 10-100 mg/kg. ^[3] Axitinib has shown single-agent activity in variable tumors, including renal cell carcinoma, thyroid cancer, non-small cell lung cancer, and melanoma.

Protocol

Kinase Assay: ^[1]	- Collapse Cellular receptor kinase phosphorylation assay: Porcine aorta endothelial (PAE) cells, which overexpress full-length VEGFR2, PDGFRβ, Kit, and NIH-3T3, which overexpress murine VEGFR2 (Flk-1) or PDGFRα, are generated. The 96-well plates are coated with 100 μL/well of 2.5 μg/mL anti-VEGFR2 antibody, 0.75 μg/mL anti-PDGFRβ antibody, 0.25 μg/mL anti-PDGFRα antibody, 0.5 μg/mL anti-KIT antibody, or 1.20 μg/mL anti-Flk-1 antibody to prepare ELISA capture plates. Then phosphorylation of RTK is measured by ELISA.
Cell Research: ^[2]	- Collapse Cell lines: HUVEC, SH-SY5Y, IGR-N91 and IGR-NB8 cells Concentrations: 1 nM - 10 μM Incubation Time: 72 hours Method: Cells are seeded in a 96-well plate at a density of 5 × 10⁴ and cultured for 24 hours. Axitinib is added to the cells at concentrations ranging from 1 nM to 10 μM. Cell viability is measured after 72 hours by MTS tetrazolium substrate and IC50 values are calculated. (Only for Reference)
Animal Research: ^[3]	- Collapse Animal Models: BT474 breast cancer cells are implanted subcutaneously into Immune-deficient female mice (Nu/nu; age 8-12 weeks). Dosages: 10, 30 or 100 mg/kg Administration: Oral daily (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	35 mg/mL warmed (90.56 mM)
	Water	Insoluble
	Ethanol	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Axitinib (AG 013736) SDF

Molecular Weight	386.47
Formula	C₂₂H₁₈N₄OS
CAS No.	319460-85-0
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)C=CC4=CC=CC=N4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04682587	Active not recruiting	Drug: Axitinib\|Drug: Avelumab\|Drug: Pembrolizumab	Renal Cell Carcinoma	Pfizer	February 24 2021	--
NCT04637204	Completed	Drug: Cabozantinib\|Drug: Axitinib	Renal Cell Carcinoma	Ipsen	November 24 2020	--
NCT04555603	Active not recruiting	Drug: Inlyta\|Drug: Bavencio\|Drug: Keytruda	Renal Cell Carcinoma	Pfizer	September 15 2020	--
NCT04522323	Active not recruiting	Biological: MEDI5752\|Drug: Axitinib	Advanced Renal Cell Carcinoma	MedImmune LLC	August 5 2020	Phase 1
NCT04459663	Not yet recruiting	Drug: Toripalimab injection combine with Axitinib	Non-small Cell Lung Cancer	Li Zhang MD\|Sun Yat-sen University	August 31 2020	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
We would like to store at -80℃ after it dissolved in CMC. Do you have any infomation about the suggested concentration in CMC?
Answer:
Axitinib in 0.5% CMC at up to 30mg/ml is a suspension for oral gavage administration only. We don't suggest customer to freeze down the solution but to make fresh if possible. Customer can store it for 1-2 weeks at 4 degree for continuous use.

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Selective VEGFR Inhibitors

Vandetanib (ZD6474) : VEGFR2-selective, IC50=40 nM.
Most Potent VEGFR Inhibitor

Cabozantinib (XL184, BMS-907351) : VEGFR2, IC50=0.035 nM.
FDA-approved VEGFR Inhibitor

Regorafenib (BAY 73-4506) : Approved by FDA for metastatic colorectal cancer and advanced gastrointestinal stromal tumors.
Classic VEGFR Inhibitor

Nintedanib (BIBF 1120) : Potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50 of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM. Phase 3.

Related VEGFR Products

SU5402 ^New

SU5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC50 of 20 nM, 30 nM, and 510 nM for VEGFR2, FGFR1, and PDGF-Rβ, respectively.
Erlotinib (OSI-774) ^New

Erlotinib (OSI-774, CP358774, NSC 718781, Tarceva) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.
Bemcentinib (R428) ^New

Bemcentinib (R428, BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).
Regorafenib (BAY 73-4506)

Regorafenib (BAY 73-4506, Fluoro-Sorafenib, Resihance, Stivarga) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit (c-Kit), RET (c-RET) and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively. Regorafenib induces autophagy.
Cabozantinib (BMS-907351)

Cabozantinib (XL184, BMS-907351) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM in cell-free assays, respectively. Cabozantinib induces PUMA-dependent apoptosis in colon cancer cells via AKT/GSK-3β/NF-κB signaling pathway.
Nintedanib (BIBF 1120)

Nintedanib (BIBF 1120, Intedanib, Vargatef, Ofev) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50 of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM in cell-free assays. Phase 3.
Vandetanib (ZD6474)

Vandetanib (ZD6474) is a potent inhibitor of VEGFR2 with IC50 of 40 nM in a cell-free assay. It also inhibits VEGFR3 and EGFR with IC50 of 110 nM and 500 nM, respectively. Not sensitive to PDGFRβ, Flt1, Tie-2 and FGFR1 with IC50 of 1.1-3.6 μM. No activity against MEK, CDK2, c-Kit, erbB2, FAK, PDK1, Akt and IGF-1R with IC50 above 10 μM. Vandetanib (ZD6474) increases apoptosis and induces autophagy by increasing the level of reactive oxygen species (ROS).
Lenvatinib (E7080)

Lenvatinib (E7080) is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/β in cell-free assays. Lenvatinib (E7080) also inhibits FGFR1-4, PDGFR, Kit (c-Kit), RET (c-RET), and shows potent antitumor activities. Phase 3.
Pazopanib

Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms/CSF1R with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively. Pazopanib induces cathepsin B activation and autophagy.
Pazopanib HCl (GW786034 HCl)

Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively. Pazopanib induces autophagic Type II cell death.

Features:A multi-kinase inhibitor.

Choose Your Country or Region

By Signaling Pathways

By product type

Axitinib (AG 013736)